Is 3671 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6
Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 3671 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 3671 (¥856) is trading below our estimate of fair value (¥1571.39)
Significantly Below Fair Value: 3671 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 3671?
Key metric: As 3671 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
The above table shows the Price to Earnings ratio for 3671. This is calculated by dividing 3671's market cap by their current
earnings.
What is 3671's PE Ratio?
PE Ratio
11x
Earnings
JP¥467.00m
Market Cap
JP¥5.14b
3671 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Price-To-Earnings vs Industry: 3671 is good value based on its Price-To-Earnings Ratio (11x) compared to the Asian Healthcare Services industry average (23.9x).
Price to Earnings Ratio vs Fair Ratio
What is 3671's PE Ratio
compared to its
Fair PE Ratio?
This is the expected PE Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
3671 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio
11x
Fair PE Ratio
n/a
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 3671's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.